Stocktoria

IMMUCELL CORP /DE/ ICCC

Nasdaq · stock · In Vitro & In Vivo Diagnostic Substances · website · IPO 1987-05-01

IMMUCELL CORP /DE/ statistics & valuation

Market cap$88.6M
P / S3.2×
P / B3.3×
P / FCF72.3×
Net margin-3.8%
Return on equity-3.8%
FCF margin4.4%
Net debt$5.3M
Net debt / EBITDA1.2×
Enterprise value USD$93.9M
EV / EBITDA21.2×
Earnings yield EBIT/EV1.8%
Return on capital4.3%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Net margin (%)
-1.60% -21.10% -9.40% -6.70% -0.40% -13.40% -33.10% -8.10% -3.80% 2016201720182019202020212022202320242025
Gross margin (%)
50.10% 47.30% 49.10% 44.70% 45.00% 41.20% 22.10% 30.00% 41.40% 2016201720182019202020212022202320242025
Operating margin (%)
-2.30% -13.20% -7.00% -9.00% 1.30% -12.40% -32.90% -6.20% 6.00% 2016201720182019202020212022202320242025
Return on equity (%)
2.60% -0.70% -10.70% -4.50% -3.60% -0.20% -8.20% -23.10% -7.80% -3.80% 2016201720182019202020212022202320242025
Shares outstanding
4.8M 5.5M 5.6M 7.2M 7.2M 7.7M 7.7M 7.8M 9.0M 9.0M 2016201720182019202020212022202320242025
Net debt ($)
$5.2M $6.7M $2.1M $2.5M -$9.4M $4.4M $5.3M $5.3M 2016201720182019202020212022202320242025
Share buybacks ($)
2016201720182019202020212022202320242025
Return on assets (%)
2.10% -0.50% -7.10% -3.30% -2.50% -0.20% -5.60% -13.20% -4.80% -2.40% 2016201720182019202020212022202320242025
Free cash flow margin (%)
-159.00% -21.90% -8.40% -18.00% -8.60% -29.70% -37.60% -0.40% 4.40% 2016201720182019202020212022202320242025
Debt / equity (×)
0.38× 0.43× 0.29× 0.34× 0.02× 0.34× 0.33× 0.34× 2016201720182019202020212022202320242025
EPS ($)
$0.12 -$0.03 -$0.42 -$0.19 -$0.14 -$0.01 -$0.32 -$0.75 -$0.26 -$0.12 2016201720182019202020212022202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

P / E vs its own history

IMMUCELL CORP /DE/ trades at about 91.5× earnings — below its 10-year norm (10-year range 15.4×–127.7×, median 107.2×).

15.4× 127.7×

Shaded band = 10-year range (15.4×–127.7×); dot = today's 91.5×.

Historical P/E = month-end price near each fiscal year-end ÷ that year's EPS. A read on whether the stock is cheap or dear relative to how it has typically been valued — not a forecast.

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Gross margin41.4%30.0%22.1%41.2%45.0%44.7%49.1%47.3%50.1%—
Operating margin6.0%-6.2%-32.9%-12.4%1.3%-9.0%-7.0%-13.2%-2.3%—
Net margin-3.8%-8.1%-33.1%-13.4%-0.4%-6.7%-9.4%-21.1%-1.6%—
FCF margin4.4%-0.4%-37.6%-29.7%-8.6%-18.0%-8.4%-21.9%-159.0%—
Return on assets-2.4%-4.8%-13.2%-5.6%-0.2%-2.5%-3.3%-7.1%-0.5%2.1%
Return on equity-3.8%-7.8%-23.1%-8.2%-0.2%-3.6%-4.5%-10.7%-0.7%2.6%
Debt / equity0.34×0.33×—0.34×0.02×0.34×0.29×0.43×0.38×—
Current ratio4.263.412.734.566.425.505.292.503.646.97

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.